论文部分内容阅读
目的:探讨联合P504s/P63免疫组化对前列腺癌诊断准确度改善及其临床预后价值。方法:采用免疫组化对3个组(前列腺癌、上皮内瘤、良性前列腺增生)标本的P504s/P63表达进行检测并比较;评估前列腺癌诊断准确度,分析前列腺癌组P504s表达与3个临床预后因素(前列腺特异性抗原水平,Gleason评分及临床疾病分期)之间的相关性。结果:前列腺癌组全呈现P504s阳性表达,P63阴性表达;上皮内瘤组一半表达P504s;良性前列腺增生组都表达P63,但没表达P504s。3组之间的P504s及P63表达均有显著差异。联合P504s/P63免疫组化检测前列腺癌的敏感度与特异度分别为96.97%及100%。P504s的表达与前列腺癌3个临床预后因素正相关。结论:P504s/P63双染免疫组化是一个高敏感性、高特异性的前列腺癌诊断手段,可提高对早期前列腺癌的检出率,并对预后准确性的判断和治疗方案的选择有一定帮助。
Objective: To investigate the combination of P504s / P63 immunohistochemistry in improving the diagnostic accuracy of prostate cancer and its clinical prognostic value. Methods: The expression of P504s / P63 in three groups (prostatic cancer, intraepithelial neoplasia and benign prostatic hyperplasia) was detected by immunohistochemistry. The diagnostic accuracy of prostate cancer was evaluated. The expression of P504s in prostate cancer was compared with that in three clinical Prognostic Factors (Prostate Specific Antigen Levels, Gleason Score, and Clinical Disease Staging). Results: The positive expression of P504s in prostate cancer group and the negative expression in P63 were found in the group of prostate cancer. The expression of P504s in the group of intraepithelial neoplasia was P504s. The expression of P63 was not observed in the group of benign prostatic hyperplasia. P504s and P63 expression between the three groups were significantly different. The sensitivity and specificity of combined P504s / P63 immunohistochemical detection of prostate cancer were 96.97% and 100% respectively. P504s expression and prostate cancer 3 clinical prognostic factors. Conclusion: P504s / P63 double staining immunohistochemistry is a highly sensitive and specific method for the diagnosis of prostate cancer, which can improve the detection rate of early stage of prostate cancer. And the choice of prognosis accuracy and treatment options are certain help.